- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03986541
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Association Between Tumour Amphiregulin, Epiregulin and Epidermal Growth Factor Receptor (EGFR) Expression and Response to Anti-EGFR Agents in Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
The anti-EGFR agents, cetuximab and panitumumab are approved by NICE for the first-line treatment of patients with RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC). However RAS-wt status is not sufficient to guarantee anti-EGFR benefit. Differential tumour expression of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), as well as the EGFR receptor itself, are putative predictive biomarkers for response to anti-EGFR agents and may therefore help better identify patients who will benefit from treatment.
Objectives:
This study aims to assess the utility of tumour AREG, EREG and/or EGFR expression, alone or in combination, as predictive biomarkers for response to anti-EGFR agents in aCRC. The investigators will develop a scoring system and categorical cut off points to differentiate AREG/EREG/EGFR positive and negative cases and correlate these with response to therapy as assessed by:
Primary endpoint: Progression Free Survival (PFS) Secondary endpoints: Overall Survival (OS), Objective Response Rate (ORR), Disease Control Rate (DCR) Finally, the investigators will utilise digital pathology and artificial intelligence (AI) technologies to automate as far as possible the process of evaluating AREG/EREG/EGFR status.
During the study, the investigators will monitor the costs of implementing the test and time taken to derive test results in order to facilitate cost-effectiveness calculations and assess the feasibility of delivering the test in future routine clinical practice.
Study Design:
A multicentre UK observational cohort study (retrospective and prospectively recruited cohorts).
Study population:
Patients with RAS-wt aCRC who received or are receiving standard care palliative treatment with an anti-EGFR agent and chemotherapy of physician's choice. Within the retrospective cohort, patients who received single agent anti-EGFR therapy under previous Cancer Drugs Fund criteria will be accepted.
Key Inclusion Criteria:
- Biopsy proven advanced colorectal adenocarcinoma at time treatment commenced (either inoperable metastatic disease at diagnosis or inoperable recurrent disease)
- Aged 18 or over at time treatment commenced
- The patient has received or has consented to receive treatment with cetuximab or panitumumab
Key Exclusion Criteria:
- Stage I, II or III colorectal adenocarcinoma
- RAS mutant disease
- Eligible for potentially curative surgery (prospective cohort)
- Underwent cancer surgery subsequent to anti-EGFR therapy (retrospective cohort)
- Unable to provide informed consent (with the exception of patients in the retrospective cohort who have passed away)
Procedures:
The study is observational and does not involve participants undergoing any study-specific investigations or treatments. Results of routine investigations and outcomes from standard care with an anti-EGFR agent will be collected from medical notes and, for the prospective cohort, during routine clinic appointments. Date of death will also be recorded. Initial and follow-up radiological and clinical assessments will occur as per local standard practice. Previously obtained pathological specimens will be retrieved for immunohistochemical analysis of tumour AREG, EREG and EGFR expression.
Treatment During Study:
This study will observe outcomes from standard first line palliative treatment of RAS-wt aCRC. In line with current NICE guidelines, such treatment will involve physician's choice of panitumumab or cetuximab in combination with:
- 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) or
- 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) Where RAS mutation status is only available after commencement of treatment and the anti-EGFR agent is therefore commenced in cycle two, patients may still be recruited to the study.
It is anticipated that most patients in the retrospective cohort will have received current standard first line palliative treatment of RAS-wt aCRC as above. However, patients who were treated with single agent anti-EGFR therapy under previous Cancer Drugs Fund criteria may still be recruited.
Statistical Methods:
Sample size:
Data from 480 patients will be collected for the retrospective cohort and 480 patients will be recruited to the prospective cohort.
Primary endpoint analysis:
PFS will be calculated from date of commencing treatment to date of progression or death from any cause (whichever is sooner). Time of progression will be determined clinically or radiologically by the participant's treating oncologist. Where the anti-EGFR agent was commenced in cycle 2, the definition of the start of treatment will remain cycle 1 day 1 of palliative chemotherapy.
Key secondary endpoint analyses:
OS will be determined from date of commencing treatment to death. ORR is the proportion of patients with documented radiological complete or partial response on first follow-up imaging whereas DCR is the proportion of patients with either radiologically stable disease or a response. For the purpose of these analyses, those without follow-up imaging will be assumed to have progressed.
AREG/EREG/EGFR expression will be assessed as a continuous variable and using dichotomous classifiers ('high' and 'low') for each marker individually and in combination. Subgroup analyses will be performed for BRAF mutation positive tumours, primary tumour location (right versus left colon, and rectum) and previous surgery (primary excised versus in situ). Within the retrospective cohort, those who received single agent anti-EGFR therapy under previous Cancer Drugs Fund criteria will be analysed separately.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Leeds, United Kingdom, LS9 7TF
- St James's University Hospital
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
-
Nottingham, United Kingdom, NG7 2UH
- Nottingham University Hospitals Nhs Trust
-
Sheffield, United Kingdom, S5 7AU
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Wirral, United Kingdom, CH63 4JY
- The Clatterbridge Cancer Centre
-
-
West Yorkshire
-
Huddersfield, West Yorkshire, United Kingdom
- Calderdale and Huddersfield NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Biopsy proven advanced colorectal adenocarcinoma at time treatment commenced (either inoperable metastatic disease at diagnosis or inoperable recurrent disease)
- Aged 18 or over at time treatment commenced
- The patient has received or has consented to receive treatment with cetuximab or panitumumab
Exclusion Criteria:
- Stage I, II or III colorectal adenocarcinoma
- RAS mutant disease
- Eligible for potentially curative surgery (prospective cohort)
- Underwent cancer surgery subsequent to anti-EGFR therapy (retrospective cohort)
- Unable to provide informed consent (with the exception of patients in the retrospective cohort who have passed away)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Retrospective cohort
Patients with advanced colorectal cancer previously treated with an anti-EGFR agent (panitumumab or cetuximab).
|
Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
|
Prospective cohort
Patients with advanced colorectal cancer newly starting treatment with an anti-EGFR agent (panitumumab or cetuximab).
|
Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: March 2023
|
PFS will be calculated from date of commencing treatment to date of progression or death from any cause (whichever is sooner).
Time of progression will be determined clinically or radiologically by the participant's treating oncologist.
|
March 2023
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: March 2023
|
OS will be determined from date of commencing treatment to death.
|
March 2023
|
Objective response rate
Time Frame: 8-12 weeks post commencement of treatment
|
ORR is the proportion of patients with documented radiological complete or partial response on first follow-up imaging.
|
8-12 weeks post commencement of treatment
|
Disease control rate
Time Frame: 8-12 weeks post commencement of treatment
|
DCR is the proportion of patients with either radiologically stable disease or a response on first follow-up imaging
|
8-12 weeks post commencement of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Philip Quirke, PhD FRCPath, University of Leeds - Institute of Medical Research at St James's
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N6AREG/EREG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer Stage IV
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingColorectal Cancer | Colorectal Cancer Stage IV | Stage IV Colorectal Cancer Positive for BRAF V600E MutationUnited States
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
Clinical Trials on Immunohistochemistry
-
Assiut UniversityNot yet recruiting
-
Groupe Francais De Pneumo-CancerologieCompletedLarge Cell Lung Cancer | Neuroendocrine Carcinoma of Lung (Diagnosis)France
-
Centre Hospitalier Universitaire, AmiensCompleted
-
University Hospital, GrenobleInstitut National de la Santé Et de la Recherche Médicale, FranceNot yet recruitingFetal Growth Retardation | Pre-eclampsia | Pre-Term
-
Centre Hospitalier Departemental VendeeCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Completed
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingHead and Neck CancerFrance
-
St. Justine's HospitalRecruitingHirschsprung Disease | Ganglion | Hirschsprung Disease, Long-Segment | HypoganglionosisCanada
-
Hillel Yaffe Medical CenterUnknown